Artivion, Inc. (NYSE:AORT) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 7.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 107,640 shares of the company's stock after selling 8,877 shares during the period. Nuveen Asset Management LLC owned approximately 0.26% of Artivion worth $3,077,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of Artivion by 2.8% in the fourth quarter. Franklin Resources Inc. now owns 21,707 shares of the company's stock worth $621,000 after acquiring an additional 600 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Artivion by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock worth $645,000 after purchasing an additional 727 shares during the period. Smartleaf Asset Management LLC increased its holdings in Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after purchasing an additional 786 shares in the last quarter. Barclays PLC raised its position in Artivion by 1.2% in the fourth quarter. Barclays PLC now owns 71,697 shares of the company's stock valued at $2,051,000 after purchasing an additional 820 shares during the period. Finally, New York State Common Retirement Fund raised its position in Artivion by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 41,017 shares of the company's stock valued at $1,173,000 after purchasing an additional 1,000 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Stock Down 0.8%

Shares of NYSE:AORT traded down $0.22 during trading on Tuesday, hitting $28.49. The company's stock had a trading volume of 369,637 shares, compared to its average volume of 330,895. The company has a market capitalization of $1.22 billion, a PE ratio of -1,424.30 and a beta of 1.54. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock's 50-day moving average price is $25.70 and its two-hundred day moving average price is $27.40.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The business had revenue of $98.98 million for the quarter, compared to analysts' expectations of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, sell-side analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 10,548 shares of the company's stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $29.13, for a total transaction of $307,263.24. Following the sale, the senior vice president now owns 105,332 shares in the company, valued at $3,068,321.16. This represents a 9.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider John E. Davis sold 15,100 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total value of $356,511.00. Following the transaction, the insider now directly owns 208,778 shares in the company, valued at approximately $4,929,248.58. This represents a 6.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 65,414 shares of company stock valued at $1,716,731 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Analyst Ratings Changes

AORT has been the subject of several analyst reports. Stifel Nicolaus decreased their target price on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Citizens Jmp raised Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $32.00 price target on shares of Artivion in a report on Tuesday, May 6th. Finally, JMP Securities reiterated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.